Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | $25,556 | $27,771 |
| Operating expenses: | ||
| Research and development | 33,991 | 41,180 |
| General and administrative | 26,202 | 14,130 |
| Total operating expenses | 60,193 | 55,310 |
| Loss from operations | (34,637) | (27,539) |
| Other income (expense), net: | ||
| Interest income | 2,653 | 4,413 |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s R&D?
- AnaptysBio, Inc. (ANAB) reported R&D of $33.99M in Q1 2026.
- How has AnaptysBio, Inc.'s R&D changed year-over-year?
- AnaptysBio, Inc.'s R&D decreased by 17.5% year-over-year, from $41.18M to $33.99M.
- What is the long-term trend for AnaptysBio, Inc.'s R&D?
- Over 4 years (2021 to 2025), AnaptysBio, Inc.'s R&D has grown at a 8.4% compound annual growth rate (CAGR), from $98.5M to $135.97M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about AnaptysBio, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude